Grufity logoGrufity logo

FATE

19.26USD-0.57(-2.87%)Market Closed

Fate Therapeutics Inc

Market Summary

USD19.26-0.57Market Closed
-2.87%

FATE Stock Price

RSI Chart

Valuation

Market Cap

2.1B

Price/Earnings

-8.33

Price/Sales

30.98

Price/Cashflow

-9.55

Price/Sales

Profitability

Return on Equity

-43.71%

Return on Assets

-31.44%

Fundamentals

Revenue

Revenue (TTM)

68.3M

Revenue Y/Y

38.3%

Revenue Q/Q

0.73%

Earnings

Earnings (TTM)

-253.7M

Earnings Y/Y

-38.11%

Earnings Q/Q

-15.85%

Price Action

52 Week Range

17.1066.56
(Low)(High)

Last 7 days

-1.9%

Last 30 days

-11.6%

Last 90 days

-25.9%

Trailing 12 Months

-63.3%

Financial Health

Current Ratio

6.55

Debt/Equity

0.03

Debt/Cashflow

-8.45

Investor Care

Shares Dilution (1Y)

1.91%

Diluted EPS (TTM)

-2.64

Peers (Alternatives to Fate Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
3.93% 44.98%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
7.49% 27.03%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
16.17% -46.79%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
2.68% 20.17%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
5.27% 39.87%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
-2.67% -35.96%
-12.87
32.5
-41.50% -607.58%
3.4B
-
-11.41% -45.13%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-11.65% -63.33%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
3.17% -38.24%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-27.72% -92.37%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-26.30% -79.52%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
7.36% -33.10%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-21.49% -58.93%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-29.05% -90.98%
-13.56
44.06
522.71% -129.91%
218.9M
-
-28.90% -83.56%
-2.36
609.63
-71.03% -64.56%

Financials for Fate Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue8.1%6863565548
Operating Expenses13.4%350308273236206
  S&GA Expenses12.5%7466575143
  R&D Expenses13.7%276243216185163
Net Income-9.0%-253.72-232.72-212.15-196.58-211.96
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-6.0%8078589219851,016
  Current Assets0.0%599599633694713
    Cash Equivalents-14.6%556513412977
  Net PPE5.4%10398927559
  Current Liabilities17.5%92788192106
Shareholder's Equity-8.4%580633679730752
  Retained Earnings-9.1%-910.88-834.77-769.08-700.46-657.15
  Additional Paid-In Capital1.6%1,4951,4711,4491,4311,409
Shares Outstanding0.3%9797969594
Float-6,960----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-10.5%-221.44-200.39-162.87-113.24-110.60
  Share Based Compensation12.0%6861544943
Cashflow From Investing29.6%182141-324.02-561.33-693.43
Cashflow From Financing-1.8%1818453455448

Risks

What is the probability of a big loss on FATE?

100%


Probability that Fate Therapeutics stock will be more than 20% underwater in next one year

98.1%


Probability that Fate Therapeutics stock will be more than 30% underwater in next one year.

30.8%


Probability that Fate Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does FATE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Fate Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on FATE

24.3%


7-Year Cumulative Returns

34.6%


5-Year Cumulative Returns

7.2%


3-Year Cumulative Returns

What are the long-term rolling returns for FATE?

FIve years rolling returns for Fate Therapeutics.

Which funds bought or sold FATE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
117
2,000
-%
2022-11-22
Capital Impact Advisors, LLC
ADDED
22.67
-2,000
408,000
0.41%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.84
-282,000
2,226,000
-%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-
-
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-12,000
-
-%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
207,000
207,000
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
-26,000
242,000
-%
2022-11-15
Bruce & Co., Inc.
UNCHANGED
-
-135,000
1,277,000
0.35%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
150.29
3,342,240
5,987,460
0.01%
2022-11-15
JANE STREET GROUP, LLC
REDUCED
-46.28
-283,000
267,000
-%

1–10 of 44

Latest Funds Activity

Are funds buying FATE calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own FATE

Fate Therapeutics News

Digital Journal

Androgenetic Alopecia Treatment Market Value Projected to Expand by 2030 | Histogen Inc, Cipla Limited, Aclaris Therapeutics.14 hours ago

FierceBiotech

FATE Fair Value

Recent SEC filings of Fate Therapeutics

View All Filings
Date Filed Form Type Document
Nov 07, 2022
8-K
Current Report
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for FATE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-18
Dulac Edward J III
SOLD
-153,051
29.8055
-5,135
Chief Financial Officer
2022-07-22
Wolchko J Scott
SOLD
-200,356
32.0775
-6,246
President and CEO
2022-07-22
Wolchko J Scott
ACQUIRED
16,864.2
2.7
6,246
President and CEO
2022-07-21
Wolchko J Scott
ACQUIRED
81,000
2.7
30,000
President and CEO
2022-07-21
Wolchko J Scott
SOLD
-986,361
32.8787
-30,000
President and CEO
2022-07-07
Valamehr Bahram
ACQUIRED
46,841.3
2.73
17,158
Chief R&D Officer
2022-07-07
Valamehr Bahram
SOLD
-518,686
30.23
-17,158
Chief R&D Officer
2022-07-06
Valamehr Bahram
ACQUIRED
25,628.7
3.26813
7,842
Chief R&D Officer
2022-07-06
Valamehr Bahram
SOLD
-235,809
30.07
-7,842
Chief R&D Officer
2022-07-05
Plavsic Mark
SOLD
-91,524.6
24.61
-3,719
Chief Technical Officer

1–10 of 50

J. Scott Wolchko
450
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Collaboration revenue$ 14,981$ 14,225$ 51,944$ 38,777
Type of Revenue [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:    
Research and development$ 79,817$ 53,130$ 233,263$ 146,004
General and administrative21,55515,71862,64840,385
Total operating expenses101,37268,848295,911186,389
Loss from operations(86,391)(54,623)(243,967)(147,612)
Other income:    
Interest income1,7872892,9621,012
Change in fair value of stock price appreciation milestones89111,02615,1313,070
Other income:15005160
Total other income (expense)2,82811,31518,6094,082
Net loss(83,563)(43,308)(225,358)(143,530)
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale securities, net12813(2,491)(143)
Comprehensive loss$ (83,435)$ (43,295)$ (227,849)$ (143,673)
Earnings Per Share, Basic$ (0.86)$ (0.45)$ (2.33)$ (1.52)
Earnings Per Share, Diluted$ (0.86)$ (0.45)$ (2.33)$ (1.52)
Weighted Average Number of Shares Outstanding, Basic97,023,50695,409,20196,692,97494,396,485
Weighted Average Number of Shares Outstanding, Diluted97,023,50695,409,20196,692,97494,396,485

FATE Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 82,093$ 133,583
Accounts receivable10,2238,676
Short-term investments and related maturity receivables423,043482,327
Prepaid expenses and other current assets19,9708,826
Total current assets535,329633,412
Long-term investments13,939100,664
Property and equipment, net109,11891,529
Operating lease right-of-use assets67,37870,720
Restricted cash15,22715,227
Collaboration contract asset8,3259,870
Other assets3333
Total assets749,349921,455
Current liabilities:  
Accounts payable9,5938,612
Accrued expenses50,14942,412
CIRM award liability, current portion3,2003,200
Deferred revenue, current portion35,24121,483
Operating lease liabilities, current portion5,7555,577
Total current liabilities103,93881,284
Deferred revenue, net of current portion12,40727,124
CIRM award liability, net of current portion800800
Operating lease liabilities, net of current portion105,164109,241
Stock price appreciation milestones9,03724,168
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; authorized shares-5,000,000 at September 30, 2022 and December 31, 2021; Class A Convertible Preferred shares issued and outstanding-2,794,549 at September 30, 2022 and December 31, 202133
Common stock, $0.001 par value; authorized shares-250,000,000 at September 30, 2022 and December 31, 2021; issued and outstanding-96,862,797 at September 30, 2022 and 95,726,962 at December 31, 20219796
Additional paid-in capital1,515,5971,448,584
Accumulated other comprehensive loss(3,253)(762)
Accumulated deficit(994,441)(769,083)
Total stockholders’ equity518,003678,838
Total liabilities and stockholders’ equity$ 749,349$ 921,455